For what condition is reteplase primarily approved for use?

Reteplase is primarily approved for use in the treatment of acute myocardial infarction (AMI), also known as a heart attack. It is a thrombolytic agent that works by dissolving blood clots that are obstructing blood flow to the heart muscle. This action is crucial in the context of AMI, where time is of the essence to restore circulation and minimize damage to the myocardium. Administering reteplase quickly can significantly reduce mortality and improve outcomes for patients experiencing a heart attack.

Other conditions listed, such as chronic heart failure, ischemic stroke, and pulmonary embolism, may involve different therapeutic approaches and medications that are more specifically indicated for those conditions. For example, while some thrombolytic agents may also be utilized in the context of ischemic stroke, reteplase itself is not primarily indicated for that condition, nor is it used for chronic heart failure or pulmonary embolism as a standard treatment option.